Tagatose: From a sweetener to a new diabetic medication?

Expert Opinion on Investigational Drugs

Volumn 19, Issue 2, 2010, Pages 285-294

  Espinosa, Ikna ^a   Fogelfeld, Leon ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Artificial sweetener; Diabetes medication; Hexose; Postprandial hyperglycemia; Sugar substitute; Tagatose

Indexed keywords

PLACEBO; TAGATOSE;

ABDOMINAL PAIN; BLOATING; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HUMAN; HYPERGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION; GLYCOGENOLYSIS; HEXOSES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIVER; SWEETENING AGENTS;

EID: 74549165469     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903501521     Document Type: Review

References (56)

1. Levin GV, Zehner LR, Saunders JP. Sugar substitutes: their energy values, bulk characteristics and potential health benefits. Am J Nutr 1995;62(Suppl):1161S-8S
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32(1):193-203
3. Gardner DG, Shoback D. Greenspan's basic and clinical endocrinology. 8th edition. McGraw Hill Medical, New York; 2007. p. 697-701
4. Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag 2008;4(6):1189-1195
5. Bastarrachea RM, Montero JC, Saavedra-Gajardo I, et al. Molecular targets for new drug discovery to treat type 2 diabetes and obesity. Rev Med Chil 2008;136(1):107-117
6. Normen L, Laerke HN, Jensen BB, et al. Small-bowel absorption of D-tagatose and related effects on carbohydrate digestibility: an ileostomy study. Am J Clin Nutr 2003;73(1):105-110
7. Livesey G, Brown JC. D-Tagatose is a bulk sweetener with zero energy determined in rats. J Nutr 1996;126(6):1601-1609
8. Levin GV. Tagatose, the new GRAS sweetener and health product. J Med Food 2002;5(1):23-36
9. Donner TW, Wilbur JF, Ostrowski D. D-Tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obes Metab 1999;1(5):285-291
10. Ibrahim OO, Spradlin JE. Process for manufacturing D-tagatose. 2000. Available from: http://www.uspto.gov/patft/index.html
11. Kim P. Current studies on biological tagatose production using L-arabinose isomerase: a review and future prospective. Appl Microbiol Biotechnol 2004;65(3):243-249
12. Buemann B, Toubro S, Astrup A. Human gastrointestinal tolerance to D-tagatose. Regul Toxicol Pharmacol 1999;29:S71-7
13. Buemann B, Toubro S, Raben A, Astrup A. Human tolerance to a single high dose D-tagatose. Regul Toxicol Pharmacol 1999;29:S66-70
14. Buemann B, Toubro S, Raben A, et al. The acute effect of D-tagatose on food intake in human subjects. Br J Nutr 2000;84(2):227-231
15. Laerke HN, Jensen BB. D-Tagatose has a low small intestine digestibility but high large intestinal fermentability in pigs. J Nutr 1999;129(5):1002-1009
16. Bertelsen H, Andersen H, Tvede M. Fermentation of D-tagatose by human intestinal bacteria and dairy lactic acid bacteria. Microb Ecol Health Dis 2001;13:87-95
17. Pyun YR, Kim BC, Lee HS, et al. Thermostable L-Arabinose Isomerase and process for preparing D-tagatose. 2005. Available from: http://www.uspto.gov/ patft/index.html. [cited]
18. Hansen OC, Jorgensen F, Stougaard P, et al. Thermostable isomerase and use thereof, in particular for producing tagatose. 2006. Available from: http:// www.uspto.gov/patft/index.html. [cited]
19. Johansan HN, Jensen BB. Recovery of energy as SCFA after microbial fermentation of D-tagatose. Int J Obes 1997;21(Suppl 2):S50
20. Bar A. D-tagatose, dossier prepared and submitted by Bioresco on behalf of Arla Food Ingredients amba, Viby Denmark for evaluation pursuant to EU Novel Foods Regulation (EC) 258/97 by the UK Advisory Committee on Novel Foods and Processes. 2004. Available from: http:// www.foodstandards.gov.uk/multimedia/ pdfs/tagatoseapplicationdossier.pdf. [cited]
21. FSANZ. Final Assessment Report, Application A472, D-tagatose as a novel food. 2004. Available from: http://www. foodstandards.gov.au/-srcfiles/ A472-D-tagatose-FAR.pdf. [cited]
22. Buemenn B, Toubro S, Astrup A. D-Tagatose, a stereoisomer of D-Fructose, increases hydrogen production in humans without affecting 24-hour expenditure or respiratory exchange ratio. J Nutr 1998;128:1481-1486
23. Buemann B, Toubro S, Holst JJ, et al. D-Tagatose, a stereoisomer of D-fructose increases blood uric acid oncentration. Metabolism 2000;49(8):969-976
24. Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 2008;10:109-134
25. Seri K, Sanai K, Negeshi S, Akino T. Prophylactic and remedial preparation for disease attendant on hyperglycemia and wholesome food. 1993:US
26. Madenokoji N, Iino H, Shimizu T, et al. Blunting effect of D-tagatose on blood glucose when administered orally with glucose in volunteer donors of boundary glycemic control. J Jpn Soc Clin Nutr 2003;25:21-28
27. Sigrist-Nelson K, Hopfer U. A distinct D-fructose transport system in isolated brush border membrane. Biochem Biophys Acta 1974;367:247-254
28. Van den berghe G, Hue L, Hers HG. Inhibition in vivo of the hyperglycemic action of glucagon: study of the pathogeny of hereditary fructose intolerance. Pediatr Res 1974;8:910
29. Bollen M, de Ruysscher D, Stalmans W. On the mechanism of hepatic glycogenolysis induced by anoxia or cyanide. Biochem Biophys Res Commun 1983;15:1033-1039
30. Van Schaftingen E, Vandercammen A. Stimulation of glucose phosphorylation by fructose in isolated rat hepatocytes. Eur J Biochem 1989;179:173-177
31. Kruger CL, Whittaker MH, Frankos VH, Trimmer GW. 90-day oral toxicity study of D-tagatose in rats. Regul Toxicol Pharmacol 1999;29:S1-10
32. Hertel S, Wv. Saccharase/isomaltase und glucoamylase/maltase aus schweinendunndarmmukosa mit substraten und inhibition. PhD thesis, University of Hanover, Germany 1997
33. Buemann B, Gesmar H, Astrup A, Quistorff B. Effects of Oral D-Tagatose, a stereoisomer of D-Fructose on liver metabolism in man as examined by P-magnetic resonance spectroscopy. Metabolism 2000;49:1225-1339
34. Agius L. Control of glucokinase translocation in rat hepatocytes by sorbitol and the cytosolic redox state. Biochem J 1994;198:237-243
35. Agius L. The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 1998;38:303-331
36. Niculescu L, Veiga-da-Cunha M, Van Schaftingen E. Investigation on the mechanism by which fructose, hexitols, and other compounds regulate the translocation of glucokinase in rat hepatocytes. Biochem J 1997;321:239-246
37. Agius L, Peak M, Newgard CB, et al. Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. J Biol Chem 1996;271:30479-30486
38. Gergely P, Toth B, Farkas I, Bot G. Effect of fructose 1-phosphate on the activation of liver glycogen synthase. Biochem J 1985;232:133-137
39. Ercan-Fang N, Gannon MC, Rath VL, et al. Integrated effects of multiple modulators on human liver glycogen phosphorylase alpha. Am J Physiol Endocrinol Metab 2002;283(1):E29-37
40. Donner T. The metabolic effects of dietary supplementation with D-tagatose in patients with type 2 diabetes. Diabetes 2006;55(Suppl 1):A110;461P
41. Donner TW, Wilbur JF, Ostrowski D. D-tagatose: a novel therapeutic adjunct for non-insulin dependent diabetes [abstract]. Diabetes;1996;45(Suppl 2):125A
42. Masoro E. Aging and proliferative homeostasis: modulation by food restriction in rodents. Lab Anim Sci 1992;42:132-137
43. Bar A, Lina BA, de Groot DM, et al. Effects of D-tagatose on liver weight and glycogen content of rats. Regul Toxicol Pharmacol 1999;29:S11-28
44. Bar A. Characteristics and significance of D-tagatose-induced liver enlargement in rats: an interpretive review. Regul Toxicol Pharmacol 1999;29:S83-93
45. Boesch C, Ith M, Jung B, et al. Effect of oral D-tagatose on liver volume and hepatic glycogen accumulation in healthy male volunteers. Regul Toxicol Pharmacol 2001;33:257-267
46. Saunders JP, Donner TW, Sadler JH, et al. Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans. Regul Toxicol Pharmacol 1999;29:S5
47. AACE. The State of Diabetes in America: Executive Summary. 2003-2004 [Available from: http://www.aace.com/ public/awareness/stateofdiabetes/ DiabetesAmericaReport.pdf] page 1-9.
48. Finfer S, Chittock DR, Su SY, et al.; Investigators, TNS. Intensive versus conventional glucose control in critically ill patients. NEJM 2009;360:1283-1297
49. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545-2559
50. Monnier L, Colette C. Targeting prandial hyperglycemia: how important is it and how best to do this? Curr Diabetes Rep 2008;8:368-374
51. Ceriello A. The emerging role of post-prandial hyperglycemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998;15:188-193
52. Hanefield M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up. Diabetologia 1996;39:1577-1583
53. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type two diabetes mellitus. Circulation 2004;110:214-219
54. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009;8:23
55. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-1078
56. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003;290:486-494 (Pubitemid 37430502)